Navigation Links Releases Q3 Sales for Top 100 U.S. Drugs: Singulair Drops But Nexium and Abilify Remain the Leading Brands

NEW YORK, Nov. 21, 2012 /PRNewswire/ -- As in the previous quarter, proton-pump inhibitors, antipsychotics and statins remain in the top-selling therapeutic categories. Merck's asthma and allergy preventive Singulair predictably drops out of the top five drugs due to Q3 patent loss.

Top Five Drugs by Sales, Q3 2012Drug Name

Sales ($000)

% Change (previous










13.45%AstraZeneca's Nexium, not forecast to lose patent protection until May 2014, once again holds the top spot with over $1.42 billion in sales. Otsuka's leading antipsychotic Abilify continues to run a close race with Nexium, posting sales of $1.40 billion. The antidepressant and pain modifier Cymbalta and the TNF blocker Humira both break their way into the top five and exceed sales of $1.15 billion.

Top Five Sales Gains, Q3 2012

Drug Name

Gain ($000)

% Change (previous










+9.93%Humira not only moves into the top five drugs by sales, but also displaces escitalopram to claim the number-one spot for revenue gains with over $136 million. Enbrel, with a doubling of sales gains, is the only other brand besides Humira to reappear in the top five sales gain in Q3 compared to Q2 2012. Crestor, Cymbalta and Copaxone all move into the top five, approaching or exceeding double-digit gains.

Top Five Sales Losses, Q3 2012

Drug Name

Loss ($000)

% Change (previous










-41.96%Merck's Singulair drops 20 spots in sales ranking and loses over $800 million in sales due to first-time generic competition. Takeda's Actos, which has been slowly losing sales over the last 12 months, went generic in August and quickly drops 42 percent of revenue.

"Unprecedented pharmaceutical sales losses continue to make headlines in Q3 2012, highlighted by the Singulair patent expiry in August," said Philip Thornton, CEO of "But these changes can be thought of as a win-win situation -- generic availability enables cost-savings for patients, while loss of exclusivity encourages the pharmaceutical industry to further develop new and life-saving therapeutics."

Pfizer's Lipitor continues to slide and drops 68 spots to close the quarter $392 million in the negative. As expected, the total dollar revenue of Lipitor's generic counterpart atorvastatin rapidly declines, dropping by over $613 million due to the market entrance of multiple generic manufacturers and inevitable price erosion.

Lidoderm, Maxalt and Actoplus Met are the next major brands expected to feel the effect of patent loss before the year's end.

Detailed data on the top 100 drugs can be accessed at:

About is the leading online drug information resource with over eight million unique visitors per month (ComScore, October 2012). Providing free, independent, peer-reviewed, and up-to-date information at both consumer and professional levels, empowers patients and caregivers to take charge of their health and be more informed than ever before. The site includes many interactive tools and mobile apps to assist consumers, healthcare professionals and researchers, such as personal medication records, a drug interaction checker, pill identification wizard, symptom checker, pharma sales statistics and more.

For more information, visit:

This press release was issued through eReleases® Press Release Distribution. For more information, visit

Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Latest Drug Sales Data: Loss of Patent Protection Has Significant Effect, According to
2. ulrich medical USA™ Releases New Expandable Spinal Implant for US Market
3. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
4. ShelfX Releases A Fridge That Knows What You Took
5. Techne Corporation Releases Unaudited Third Quarter and Nine Month Fiscal Year 2012 Results
6. Stereotaxis Releases V-Sono™ Intracardiac Echocardiography Module for the Vdrive™ Remote Navigation System
7. Simbionix Releases Two New Platforms at the Upcoming DDW and AUA Events
8. Medical Alarm Begins Revenue Recognition from Largest Set of Orders -- Releases New Television Commercial
9. MD Bioproducts releases HLA-B27 subtype specific antibody.
10. ChemDAQ Releases First Sensor For Detection Of Peracetic Acid In Air
11. Polar Releases H7, a Preeminent Wireless Heart Rate Sensor with Bluetooth Smart
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015 USP 800 ... drug preparations (e.g. pharmacists, pharmacy technicians, nurses, physicians, ... technicians). The chapter also covers all entities which ... pharmacies, hospitals, other healthcare institutions, patient treatment clinics, ... --> --> What is ...
(Date:11/25/2015)... Asia -based venture ... and the New Investors will make a direct equity ... private placement. The financing will help IOPtima to continue ... in the treatment of glaucoma, as well as to ... system with the U.S. Food and Drug Administration, commencing ...
(Date:11/25/2015)... , November 25, 2015 Developmental, commercial, ... in boosting the profitability of pharmaceutical products, says ... and regulatory/legal strategies all play a key ... says GBI Research . --> ... a key role in boosting the profitability of pharmaceutical products, ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent Applied Drug ... need to integrate dose form selection in early phase drug development. The first ... supporting and bringing together the UK’s emerging life sciences companies, corporate partners, and ...
(Date:11/26/2015)... ... November 26, 2015 , ... PRMA Plastic Surgery is ... 2015, our surgeons performed their 6,000th free flap breast reconstruction surgery! , “What an ... every day excited to rebuild lives and it’s an honor to have served all ...
(Date:11/26/2015)... ... November 26, 2015 , ... Pixel Film ... trailer titles with ProTrailer: Vintage. This newly styled ProTrailer pack comes with 30 ... with any font, giving users limitless opportunities to stylize and create designs quickly ...
(Date:11/26/2015)... ... , ... Indosoft Inc., developer and distributor of the world-class Asterisk based contact ... and reliability. , The new Q-Suite 6 platform is based on the latest Java ... into a specific piece of software for many key components of the suite. Much ...
(Date:11/25/2015)... Indianapolis, IN (PRWEB) , ... November 25, 2015 ... ... clean water accessible for all, Water For Empowerment ™ attracts volunteers together ... on clean water by empowering women as key stakeholders in the process. The ...
Breaking Medicine News(10 mins):